Evidence map›Paper›PMID 34256905›Full record

ArticleCancer cell2021

I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment.

Jose Perez-Garcia, Maria Gion, Javier Cortes

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Jose Perez-GarciaOncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA.
Maria GionOncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Javier CortesOncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA; Breast Cancer Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. Electronic address: jacortes@vhio.net.
Instituto Cajal · ESMedSIR (Spain) · ESVall d'Hebron Institute of Oncology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

I-SPY2 platform-based phase II studies in breast cancer might speed up the development of new treatments. In this issue of Cancer Cell, Pusztai et al. report that adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increases the pathological complete response rate in patients with HER2-negative breast cancer irrespective of the hormone receptor status.

Indexed as

Breast NeoplasmsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansNeoadjuvant TherapyPhthalazinesPiperazinesAntibodies, MonoclonaldurvalumabolaparibPhthalazinesPiperazines

Identifiers

PMID34256905
OpenAlexW3182467615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.